Skip to main content
. 2023 Jun 22;64:102791. doi: 10.1016/j.redox.2023.102791

Fig. 5.

Fig. 5

IL-6 silencing mitigates the metastatic phenotype induced by NK-LAAO. (A) Phase-contrast imaging of control and IL-6-silenced A549 cells untreated or treated with 0.3 μg/ml NK-LAAO for 24 h. Scale bar: 100 μm. (B–F) qRT-PCR analysis of the mRNA levels of the EMT inducers (B) Vimentin, (C) N-cadherin, (D) Snail, (E) ZEB1, and (F) ZEB2 in control and IL-6-silenced A549 cells with or without 0.3 μg/ml NK-LAAO treatment for 24 h. (G, H) Transwell assays monitoring the (G) migratory and (H) invasive capabilities of control and IL-6-silenced A549 cells untreated or treated with 0.3 μg/ml NK-LAAO for 18 h. Scale bar: 100 μm. Error bars represent mean ± SD (n = 3). Data were analyzed using two-tailed unpaired Student's t-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, and ns (not significant) p > 0.05).